tiprankstipranks
Trending News
More News >
Repro-Med Systems, Inc. (KRMD)
:KRMD
US Market
Advertisement

REPRO-MED Systems (KRMD) Earnings Dates, Call Summary & Reports

Compare
290 Followers

Earnings Data

Report Date
Mar 04, 2026
After Close (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
-0.02
Last Year’s EPS
-0.03
Same Quarter Last Year
Based on 4 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 12, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, particularly from international markets, and successful strategic advancements in oncology and other areas. However, challenges such as domestic revenue decline, gross margin pressure, and some pipeline delays were noted.
Company Guidance
During the KORU Medical Systems third quarter 2025 earnings call, the company provided updated guidance, raising their full-year revenue expectations to between $40.5 million and $41 million, representing a growth of approximately 20% to 22%. This increase was driven by strong performance in their core subcutaneous immunoglobulin (SCIG) business, which grew 30% year-over-year, and significant international expansion, particularly with prefilled syringes in Europe. The company also achieved a gross profit growth of 21% year-over-year, maintaining a gross margin above 60%, and generating positive cash flow. Additionally, KORU is progressing strategically with new pharmaceutical collaborations and advances in oncology infusion centers. The company remains confident in sustaining long-term growth, aiming for continued revenue acceleration and profitability in the coming years.
Strong Revenue Growth
KORU Medical Systems reported revenue exceeding $10 million for the second consecutive quarter, with a year-over-year growth of 27%.
Core Business Performance
The core subcutaneous immunoglobulin (SCIG) business grew 30%, driven by international expansion and strong patient growth.
International Market Expansion
International revenue grew by 230%, with significant contributions from European markets due to conversions to prefilled syringes.
Oncology Infusion Study Success
Completed a successful US-based oncology study with high nurse and patient satisfaction, validating Core's value proposition in the oncology market.
Increased Revenue Guidance
Raised full-year revenue guidance to $40,500,000 to $41,000,000, representing 20% to 22% growth.
Positive Financial Metrics
Achieved positive adjusted EBITDA, with gross profit growth of 21% year-over-year, and generated positive cash flow.

REPRO-MED Systems (KRMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

KRMD Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 04, 2026
2025 (Q4)
-0.02 / -
-0.03
Nov 12, 2025
2025 (Q3)
-0.02 / -0.02
-0.0333.33% (<+0.01)
Aug 06, 2025
2025 (Q2)
-0.02 / 0.01
-0.01200.00% (+0.02)
May 07, 2025
2025 (Q1)
-0.03 / 0.00
-0.04
Mar 12, 2025
2024 (Q4)
-0.03 / -0.03
-0.02-50.00% (>-0.01)
Nov 13, 2024
2024 (Q3)
-0.04 / -0.03
-0.030.00% (0.00)
Aug 07, 2024
2024 (Q2)
-0.04 / -0.01
-0.0580.00% (+0.04)
May 01, 2024
2024 (Q1)
-0.04 / -0.04
-0.0520.00% (+0.01)
Mar 13, 2024
2023 (Q4)
-0.04 / -0.02
-0.0450.00% (+0.02)
Nov 08, 2023
2023 (Q3)
-0.05 / -0.03
-0.030.00% (0.00)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

KRMD Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 12, 2025
$3.78$4.35+15.08%
Aug 06, 2025
$3.26$3.87+18.71%
May 07, 2025
$2.72$3.29+20.96%
Mar 12, 2025
$3.28$2.70-17.68%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Repro-Med Systems, Inc. (KRMD) report earnings?
Repro-Med Systems, Inc. (KRMD) is schdueled to report earning on Mar 04, 2026, After Close (Confirmed).
    What is Repro-Med Systems, Inc. (KRMD) earnings time?
    Repro-Med Systems, Inc. (KRMD) earnings time is at Mar 04, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is KRMD EPS forecast?
          KRMD EPS forecast for the fiscal quarter 2025 (Q4) is -0.02.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis